CFD simulation of multiple dust explosion occurred in a flour mill

Dust explosions pose a serious hazard to both personnel and equipment in industries that handles combustible powders. Although prevention and mitigation technology of dust explosions has progressed greatly, continual accidents in the process industries demonstrate the need for improved knowledge in this area (Mercan, 2016; Russo et al., 2017). On July 16, 2007, a primary explosion followed by secondary explosions happened in the Cordero mill (Italy) and 5 persons died (Marmo et al., 2012). The accident occurred at the end of the loading operation of a tanker, when a surplus of flour was overcharged. This extra amount was then pneumatically conveyed to a silo placed in the flour-warehouses, by connecting the tanker to the pneumatic transport line through one of the tanker hoses. The flour was loaded at a low flow rate, and hence a low concentration of flour in the duct occurred. The source of ignition of the dust cloud was attributed to an electrostatic arc that took place in the pneumatic transport duct (Marmo et al., 2012). The technical enquire found signs of the explosion in the duct: internal pressure provoked evident deformation of the duct. As widely discussed in the literature (Fiorentini and Marmo 2019; Marmo et al., 2013), Computational Fluid Dynamics can be a valid aid to forensic engineering because it allows to discern the incidental sequence that is more adherent to the evidence. The aim of this work is to reproduce the conditions present in the mill at the time of the accident using the CFD-code DESC, which is being developed for simulating dust explosions in complex geometries. The results obtained from the simulations were compared to the damage observed after the accident in order to identify the more credible scenario. Simulations with different levels of flour in the silo, concentration of dust in the air mixture and position of ignition were performed. Analysis of results revealed the effect of different parameters on the severity of dust explosion, not only limited to the case study investigated, in order to adopt the appropriate prevention and protection measures

Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature

Objective: Hepatitis B virus (HBV) infection causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Furthermore, about 20% of the patients develop extrahepatic manifestations such as cryoglobulinemic vasculitis (CV), polyarteritis nodosa, non-rheumatoid arthritis, glomerulonephritis and non-Hodgkin lymphoma. This review analyzed literature data on clinical manifestations of HBV-related CV and the impact of antiviral therapy with analoques nucleotide. Methods: A PubMed search was performed to select eligible studies in the literature, up to July 2022. Results: Some studies have analyzed clinical manifestations in HBV-related CV and have investigated the role of antiviral therapy with nucleotides analogues (NAs). Clinical manifestations of CV vary from mild to moderate (purpura, asthenia and arthralgias) to severe (leg ulcers, peripheral neuropathy, glomerulonephritis, and non-Hodking lymphoma). NAs therapy leads to suppression of HBV-DNA; therefore, it is capable of producing clinical response in the majority of patients with mild to moderate symptoms. Conclusion: Antiviral therapy with NAs is the first choice for HBV suppression and control of mild to moderate disease. In severe vasculitis (glomerulonephritis, progressive peripheral neuropathy and leg ulcers), rituximab alone or with plasma-exchange is always indicated in combination with antiviral therapy

Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study

Objective. To investigate the long-term effects and safety of new direct antiviral agents (DAAs) in patients with hepatitis C virus (HCV)-related mixed cryoglobulinaemia (MC) without renal involvement.Methods. The study enrolled 22 consecutive patients, 19 received sofosbuvir-based regimen and three patients received other DAAs, individually tailored according to latest guidelines. As of December 2016, the median length of follow-up was 17 months (range 13-21).Results. Extra-hepatic manifestations at enrollment were: purpura and arthralgia (12 cases), peripheral neuropathy (10 cases) and marginal zone Blymphomas (2 cases). After a four-week DAA therapy, all patients became HCV-negative. Moreover, after 48 weeks since the beginning of DAA treatment, sustained regression of purpura and arthralgias was observed respectively in eight and in nine cases; peripheral neuropathy improved in seven cases, and cryocrit median values decreased from three (1-20) at baseline to two (1-12) after 48 weeks. Two cases with indolent marginal zone lymphomas did not show any haematological response: size and number of the involved nodes remained unchanged. In addition, the monoclonal B-cell population found in the peripheral blood in four cases did not disappear after recovery from HCV-RNA. Mild side effects occurred in nine patients, but six patients developed ribavirin-related anaemia requiring reduction of ribavirin dose.Conclusion. DAA therapy is safe and effective to eradicate HCV in MC, but seems associated with satisfactory clinical response in mild or moderate cryoglobulinaemic vasculitis and no response in B-NHL

Thermal enhancement of the antiferromagnetic exchange coupling between Fe epilayers separated by a crystalline ZnSe spacer

We have put into evidence the existence of an antiferromagnetic coupling between iron epilayers separated by a ZnSe crystalline semiconductor. The effect has been observed for ZnSe spacers thinner than 4 nm at room-temperature. The coupling constant increases linearly with temperature with a constant slope of ~5.5x 10-9 J/m2K. The mechanisms that may explain such exchange interaction are discussed in the manuscript. It results that thermally-induced effective exchange coupling mediated by spin-dependent on and off resonant tunnelling of electrons via localized mid-gap defect states in the ZnSe spacer layer appears to be the most plausible mechanism to induce the antiferromagnetic coupling.Comment: 29 pages, 8 figure

In-situ growth of nonstoichiometric CrO0.87 and Co3O4 hybrid system for the enhanced electrocatalytic water splitting in alkaline media

The development of electrocatalysts for electrochemical water splitting has received considerable attention in response to the growing demand for renewable energy sources and environmental concerns. In this study, a simple hydrothermal growth approach was developed for the in-situ growth of non-stoichiometric CrO0.87 and Co3O4 hybrid materials. It is apparent that the morphology of the prepared material shows a heterogeneous aggregate of irregularly shaped nanoparticles. Both CrO0.87 and Co3O4 have cubic crystal structures. Its chemical composition was governed by the presence of Co, Cr, and O as its main constituents. For understanding the role CrO0.87 plays in the half-cell oxygen evolution reaction (OER) in alkaline conditions, CrO0.87 was optimized into Co3O4 nanostructures. The hybrid material with the highest concentration of CrO0.87 was found to be highly efficient at driving OER reactions at 255 mV and 20 mA cm−2. The optimized material demonstrated excellent durability for 45 h and a Tafel slope of 56 mV dec−1. Several factors may explain the outstanding performance of CrO0.87 and Co3O4 hybrid materials, including multiple metallic oxidation states, tailored surface properties, fast charge transport, and surface defects. An alternative method is proposed for the preparation of new generations of electrocatalysts for the conversion and storage of energy

Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.

Tauopathies are neurodegenerative diseases characterized by intraneuronal inclusions of hyperphosphorylated tau protein and abnormal expression of brain-derived neurotrophic factor (BDNF), a key modulator of neuronal survival and function. The severity of both these pathological hallmarks correlate with the degree of cognitive impairment in patients. However, how tau pathology specifically modifies BDNF signaling and affects neuronal function during early prodromal stages of tauopathy remains unclear. Here, we report that the mild tauopathy developing in retinal ganglion cells (RGCs) of the P301S tau transgenic (P301S) mouse induces functional retinal changes by disrupting BDNF signaling via the TrkB receptor. In adult P301S mice, the physiological visual response of RGCs to pattern light stimuli and retinal acuity decline significantly. As a consequence, the activity-dependent secretion of BDNF in the vitreous is impaired in P301S mice. Further, in P301S retinas, TrkB receptors are selectively upregulated, but uncoupled from downstream extracellular signal-regulated kinase (ERK) 1/2 signaling. We also show that the impairment of TrkB signaling is triggered by tau pathology and mediates the tau-induced dysfunction of visual response. Overall our results identify a neurotrophin-mediated mechanism by which tau induces neuronal dysfunction during prodromal stages of tauopathy and define tau-driven pathophysiological changes of potential value to support early diagnosis and informed therapeutic decisions. SIGNIFICANCE STATEMENT: This work highlights the potential molecular mechanisms by which initial tauopathy induces neuronal dysfunction. Combining clinically used electrophysiological techniques (i.e., electroretinography) and molecular analyses, this work shows that in a relevant model of early tauopathy, the retina of the P301S mutant human tau transgenic mouse, mild tau pathology results in functional changes of neuronal activity, likely due to selective impairment of brain-derived neurotrophic factor signaling via its receptor, TrkB. These findings may have important translational implications for early diagnosis in a subset of Alzheimer's disease patients with early visual symptoms and emphasize the need to clarify the pathophysiological changes associated with distinct tauopathy stages to support informed therapeutic decisions and guide drug discovery.journal articleresearch support, non-u.s. gov't2016 Feb 17importe

Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis characterized by the proliferation of B-cell clones producing pathogenic immune complexes, called cryoglobulins. It is often secondary to hepatitis C virus (HCV), autoimmune diseases, and hematological malignancies. CV usually has a mild benign clinical course, but severe organ damage and life-threatening manifestations can occur. Recently, evidence in favor of rituximab (RTX), an anti-CD 20 monoclonal antibody, is emerging in CV: nevertheless, questions upon the safety of this therapeutic approach, especially in HCV patients, are still being issued and universally accepted recommendations that can help physicians in MCS treatment are lacking. A Consensus Committee provided a prioritized list of research questions to perform a systematic literature review (SLR). A search was made in Medline, Embase, and Cochrane library, updated to August 2021. Of 1227 article abstracts evaluated, 27 studies were included in the SLR, of which one SLR, 4 RCTs, and 22 observational studies. Seventeen recommendations for the management of mixed cryoglobulinemia with rituximab from the Italian Study Group of Cryoglobulinemia (GISC) were developed to give a valuable tool to the physician approaching RTX treatment in CV

Preliminary classification criteria for the cryoglobulinaemic vasculitis

To develop preliminary classification criteria for the cryoglobulinaemic syndrome or cryoglobulinaemic vasculitis (CV)